Q4 EPS Estimates for Pharming Group Boosted by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright raised their Q4 2025 EPS estimates for shares of Pharming Group in a research report issued on Wednesday, February 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.10 for the quarter, up from their prior forecast of $0.05. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million for the quarter, compared to the consensus estimate of $98.22 million.

PHAR has been the subject of a number of other research reports. Zacks Research lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Pharming Group has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Pharming Group Price Performance

PHAR opened at $16.09 on Friday. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The business has a fifty day moving average of $17.75 and a 200 day moving average of $15.29. Pharming Group has a 52-week low of $7.50 and a 52-week high of $21.34. The stock has a market cap of $1.13 billion, a P/E ratio of -1,607.39 and a beta of -0.01.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.